Medical centre joins innovation programme
Waters has added the metabolomics programme at Georgetown University Medical Centre to its Centers of Innovation programme.
Waters has added the metabolomics programme at Georgetown University Medical Centre to its Centers of Innovation programme. The programme supports scientists making breakthroughs in health and life science research, food safety, environmental protection and sports medicine.
“Professor Fornace and his laboratory have made important and highly-cited contributions to the understanding of key signalling events in cancer. His research in disease metabonomes and biomarker research is state of the art,” said Tim Riley, the director of the programme.
“The field of metabolomics has really taken off in the last six years or so,” said Professor Fornace, Professor of Biochemistry and Molecular and Cellular Biology at the centre. “It’s a demanding area of science, and since quadrupole time-of-flight mass spectrometry came on line, there has been an exponential increase in interest in metabolomics and the number of publications in this field. We are very pleased Waters has taken an interest in our research.”
Metabolomics data generated by the laboratory’s ACQUITY UPLC and Xevo G2 QTof LC–MS systems will contribute to the Georgetown Database of Cancer, a project that has compiled metabolomics data and other information from 4000 breast cancer patients to better predict the response to various cancer therapies based on patient’s genetic profiles.
For more information about the programme visit www.waters.com/waters/nav.htm?cid=10176245 and for more about Georgetown Lombardi Comprehensive Cancer Center visit lombardi.georgetown.edu
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
